Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jun 14, 2022 9:00pm
83 Views
Post# 34756829

RE:In need of an update…

RE:In need of an update…
Year3000 wrote:

On the 14/12/21
This week? Meeting with a potential strategic partner in Japan, reviewing some data from preliminary testing at Monastrerium (this is a 3-month project), working on  yet another grant application, reviewing new patent issuances, talking to potential new investors, etc.


..it's been 6 months since this tweet.... wtf is happening with the derma precise??? 


On 18/10/2021

RepliCel Files Arbitration against Shiseido to Resolve its License Dispute Regarding its Androgenetic Alopecia Cell Therapy

we are almost at 9 months since this was tweeted - granted they said it could take up to 1 year for the arbitration- surely there will be some news on this shortly

:(



That is an understatement !   It looks like they have decided that there will not be any updates or tweets until they have some positive news to release.  Not sure about negative news because it seems like there has been some bad news but they are not releasing it.  I think they have become sensitive to making time predictions and not delivering which we have seen frequently.
It is painful but I don't think we will see anything related to the Shseido Arbitration until the full year is up.  With the Dermal Injector it is most likely design and production issues.  I think a few people are beginning to wonder if the device actually works as designed.

<< Previous
Bullboard Posts
Next >>